These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35165914)

  • 1. Pharmacovigilance in China: Evolution and future challenges.
    Song H; Pei X; Liu Z; Shen C; Sun J; Liu Y; Zhou L; Sun F; Xiao X
    Br J Clin Pharmacol; 2023 Feb; 89(2):510-522. PubMed ID: 35165914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacovigilance in China: development and challenges.
    Zhao Y; Wang T; Li G; Sun S
    Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active pharmacovigilance in China: recent development and future perspectives.
    Li X; Li H; Deng J; Zhu F; Liu Y; Chen W; Yue Z; Ren X; Xia J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):863-871. PubMed ID: 29637279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.
    Zhang X; Niu R; Feng B; Guo J; Liu Y; Liu X
    Expert Opin Drug Saf; 2019 Jan; 18(1):59-68. PubMed ID: 29883236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of pharmacovigilance and reporting of adverse drug reactions in hospitals: a cross-sectional study in China.
    Zhao Z; Shen J; Shen C; Zhu B; Sun J; Yu J; Sun F; Song H
    Curr Med Res Opin; 2021 Nov; 37(11):2001-2006. PubMed ID: 34376068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacovigilance in China: current situation, successes and challenges.
    Zhang L; Wong LY; He Y; Wong IC
    Drug Saf; 2014 Oct; 37(10):765-70. PubMed ID: 25218237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
    Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
    Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The quality of spontaneous adverse drug reaction reports from the pharmacovigilance centre in western China.
    Niu R; Xiang Y; Wu T; Zhang Z; Chen Y; Feng B
    Expert Opin Drug Saf; 2019 Jan; 18(1):51-58. PubMed ID: 30574811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
    Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
    Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
    Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
    Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance implemented by patients: A necessity in the 21st century.
    Lafond J
    Therapie; 2016 Apr; 71(2):245-7. PubMed ID: 27080846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of patient reporting to the pharmacovigilance system: a systematic review.
    Inácio P; Cavaco A; Airaksinen M
    Br J Clin Pharmacol; 2017 Feb; 83(2):227-246. PubMed ID: 27558545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enlightenment of international pharmacovigilance system on establishment of pharmacovigilance system of Chinese medicine].
    Cui X; Wang LX; Liu GY; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2021 Nov; 46(21):5450-5455. PubMed ID: 34951195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting of adverse drug reactions in India: A review of the current scenario, obstacles and possible solutions.
    Mulchandani R; Kakkar AK
    Int J Risk Saf Med; 2019; 30(1):33-44. PubMed ID: 30175985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions.
    Montané E; Santesmases J
    Med Clin (Barc); 2020 Mar; 154(5):178-184. PubMed ID: 31771857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
    Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
    Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.